PDCD10-Deficiency Promotes Malignant Behaviors and Tumor Growth via Triggering EphB4 Kinase Activity in Glioblastoma.
EphB4 and EphB4 kinase inhibition
PDCD10/CCM3
glioblastoma
lentivirus mediated shRNA transduction
tumor malignant behavior
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
29
04
2020
accepted:
30
06
2020
entrez:
28
8
2020
pubmed:
28
8
2020
medline:
28
8
2020
Statut:
epublish
Résumé
We previously reported an angiogenic and tumor-suppressor-like function of programmed cell death 10 (PDCD10) in glioblastoma (GBM). However, the underlying mechanism remains to be elucidated. We hypothesized that loss of PDCD10 activates GBM cells and tumor progression via EphB4. To this end, PDCD10 was knocked down in U87 and T98g by lentiviral mediated shRNA transduction (shPDCD10). GBM cell phenotype
Identifiants
pubmed: 32850441
doi: 10.3389/fonc.2020.01377
pmc: PMC7427606
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1377Informations de copyright
Copyright © 2020 Wan, Saban, Kim, Weng, Dammann, Keyvani, Sure and Zhu.
Références
Cytokine Growth Factor Rev. 2002 Feb;13(1):75-85
pubmed: 11750881
J Cell Mol Med. 2017 Sep;21(9):1848-1858
pubmed: 28371279
Stroke. 2009 Apr;40(4):1474-81
pubmed: 19246713
Nature. 1999 Jul 1;400(6739):77-81
pubmed: 10403252
Prostate. 2016 May;76(6):543-51
pubmed: 26771762
Biomed Pharmacother. 2018 May;101:129-136
pubmed: 29482058
Cancer Res. 2009 May 1;69(9):3736-45
pubmed: 19366806
J Cell Sci. 2003 Jul 15;116(Pt 14):2823-32
pubmed: 12808016
Nature. 2016 Apr 7;532(7597):122-6
pubmed: 27027284
J Neurooncol. 2019 Jan;141(1):31-41
pubmed: 30392087
J Pharmacol Sci. 2015 Sep;129(1):65-71
pubmed: 26390965
Annu Rev Pathol. 2014;9:1-25
pubmed: 23937436
EMBO Rep. 2018 May;19(5):
pubmed: 29643120
Int J Cancer. 2015 Apr 15;136(8):1781-91
pubmed: 25274141
Curr Opin Cell Biol. 2004 Oct;16(5):580-9
pubmed: 15363810
Clin Transl Oncol. 2012 Mar;14(3):214-20
pubmed: 22374425
Eur J Med Chem. 2017 Dec 15;142:152-162
pubmed: 28780190
Clin Neurol Neurosurg. 2015 Jan;128:41-3
pubmed: 25462093
Neuro Oncol. 2016 Apr;18(4):538-48
pubmed: 26254477
Am J Pathol. 2010 Apr;176(4):2029-38
pubmed: 20133814
J Cell Mol Med. 2016 Feb;20(2):360-9
pubmed: 26647742
Cancer Res. 2013 Jan 1;73(1):184-94
pubmed: 23100466
J Cell Biochem. 2018 Aug;119(8):6408-6417
pubmed: 29236292
Tumour Biol. 2013 Feb;34(1):379-85
pubmed: 23138393
Biochim Biophys Acta Rev Cancer. 2018 Apr;1869(2):128-137
pubmed: 29369779
Angiogenesis. 2018 Nov;21(4):873-881
pubmed: 29987450
J Cell Mol Med. 2013 Mar;17(3):407-18
pubmed: 23388056
Exp Cell Res. 2006 Mar 10;312(5):642-50
pubmed: 16330025
J Clin Oncol. 2017 Jul 20;35(21):2402-2409
pubmed: 28640706
Clin Cancer Res. 2014 Nov 15;20(22):5612-9
pubmed: 25398844
Blood. 2009 Jan 1;113(1):254-63
pubmed: 18836096
J Cell Sci. 2014 Feb 15;127(Pt 4):701-7
pubmed: 24481819
PLoS One. 2011;6(9):e24426
pubmed: 21935409
Int J Cancer. 2010 Mar 1;126(5):1155-65
pubmed: 19728339
Neurosurg Focus. 2010 Sep;29(3):E1
pubmed: 20809750
Oncogene. 2005 Sep 8;24(40):6155-64
pubmed: 16091735
PLoS One. 2013 Jul 02;8(7):e67668
pubmed: 23844053
Am J Hum Genet. 2005 Jan;76(1):42-51
pubmed: 15543491
Nat Med. 2016 Sep;22(9):1033-1042
pubmed: 27548575
Pharmacol Ther. 2015 Aug;152:63-82
pubmed: 25944528
Mol Syndromol. 2013 Apr;4(4):165-72
pubmed: 23801932
Expert Rev Neurother. 2013 Nov;13(11):1263-70
pubmed: 24175724
Br J Cancer. 2014 Sep 23;111(7):1255-61
pubmed: 25144626
BMC Cancer. 2015 Oct 21;15:759
pubmed: 26490252
BMC Cancer. 2010 Nov 23;10:641
pubmed: 21092311
Mol Biol Cell. 2007 Jun;18(6):1965-78
pubmed: 17360971
BMC Cancer. 2013 May 30;13:269
pubmed: 23721559
Oncogene. 2006 Feb 2;25(5):769-80
pubmed: 16205642
Neurology. 2009 Jun 9;72(23):2044-6
pubmed: 19506228
Angiogenesis. 2010 Sep;13(3):259-67
pubmed: 20803239
Gene Expr Patterns. 2006 Jun;6(5):495-503
pubmed: 16455310